The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC).
 
William Nassib William
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck; Pfizer; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); OSI Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck
 
Won-Chul Lee
No Relationships to Disclose
 
J. Jack Lee
Consulting or Advisory Role - Abbvie
 
Heather Y. Lin
No Relationships to Disclose
 
Agda Karina Eterovic
No Relationships to Disclose
 
Adel K. El-Naggar
No Relationships to Disclose
 
Ann M. Gillenwater
No Relationships to Disclose
 
Marlese Pisegna
No Relationships to Disclose
 
Pan Tong
No Relationships to Disclose
 
Lerong Li
No Relationships to Disclose
 
Xianjun Tian
No Relationships to Disclose
 
Hai T. Tran
No Relationships to Disclose
 
Pierre Saintigny
No Relationships to Disclose
 
Jing Wang
No Relationships to Disclose
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - Abbvie; Araxes Pharma; ARIAD; Arrys Therapeutics; AstraZeneca; Biothera; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech; Genentech; Gritstone Bio; Janssen; Lilly; Loxo; Merck; Nektar; Novartis; Pfizer; Takeda; Tesaro; TRM Oncology
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche; Roche
Other Relationship - Roche
 
Scott Michael Lippman
No Relationships to Disclose
 
Phillip Andrew Futreal
Consulting or Advisory Role - GenePlus
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Merck; Novartis; Spectrum Pharmaceuticals
Research Funding - AstraZeneca (Inst); Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
Jianjun Zhang
Honoraria - CancerNet; Geneplus; Innovent Biologics; Origimed; Roche; Sino-USA Biomedical Platform; Zhejiang Cancer Hospital
Consulting or Advisory Role - AstraZeneca; Capital Medical University; Geneplus
Research Funding - Merck